OncLive® On Air
Medical Crossfire®: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application
In this podcast, experts April K.S. Salama, MD; Omid Hamid, MD; James M.G. Larkin, MD, PhD; and Sapna Patel, MD; discuss the data for immune checkpoint inhibitors used to treat advanced cutaneous squamous cell carcinoma, including a review of PD-1 versus PD-L1 inhibition.
Medical Crossfire®: Translating Risk Into Action—Redefining Adjuvant Strategies for Early HR+/HER2– Breast Cancer
In this podcast, experts Ann H. Partridge, MD, MPH; Saranya Chumsri, MD; and William J. Gradishar, MD, FASCO, FACP, discuss the roles of adjuvant chemotherapy and CDK4/6 inhibitors and neoadjuvant checkpoint inhibitors for patients with early-stage, hormone receptor–positive breast cancer.
Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer
In this podcast, experts Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; and Paolo Tarantino, MD, PhD; discuss results of recent frontline maintenance trials for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) and their implications for treatment sequencing and patient management.
Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
In this podcast, experts Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; and Millie Das, MD; discuss the latest treatment advances for extensive-stage small cell lung cancer (ES-SCLC), including how to sequence bispecific T-cell engagers and antibody-drug conjugates and ways to manage adverse events associated with these newer therapies.
The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH
In today’s episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.
In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it...
Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer
In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.
Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies
In this podcast, experts Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; and Banu Arun, MD, FASCO; discuss how genetic testing drives breast cancer management from screening and surgical decisions to targeted systemic therapies.
Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD
Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.
In today's episode, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Neil M. Iyengar, MD, an associate professor and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the director of...
FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD
Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we spoke with David Morris, MD, FACS, and Alan H. Bryce, MD. Dr Morris is the president of Urology Associates, PC, in Nashville, Tennessee. Dr Bryce is a medical oncologist and th...
The Price of Survival: Addressing Financial Toxicity in Gynecologic Oncology With Ursula A. Matulonis, MD; and Katharine M. Esselen, MD, MBA
From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.
In this episode, Dr Matulonis sat down with guest Katharine M. Esselen, MD, MBA. Dr Esselen is an attending gynecologic oncologist at Beth Israel Deaconess Medical Center and an assistant professor...
Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD
In this podcast, experts Carrie L. Kitko, MD; Miguel-Angel Perales, MD; and Amandeep Salhotra, MD, discuss GVHD prophylaxis strategies and therapies to address treatment-naive and steroid-refractory chronic GVHD.
Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD
In today’s episode, we spoke with Ticiana Leal, MD, about variability in community practice and evolving treatment strategies for patients with small cell lung cancer (SCLC). Dr Leal is a professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the medical director of the Clinical Trials Office at Winship Cancer Institute in Atlanta, Georgia.
In our exclusive interview, Dr Leal began by discussing how SCLC management can differ widely across community settings according to how patients present. Leal emphasized th...
FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. Dr Rotow is the clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Dietrich is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando.
In our exclusive interview, Drs Rotow and Dietrich discussed the significance of...
Community Practice Perspectives: Overcoming Barriers in Small Cell Lung Cancer Care: With Misty D. Shields, MD, PhD
In today’s episode, we spoke with Misty D. Shields, MD, PhD, about the realities of treating patients with small cell lung cancer (SCLC) in the community setting and how emerging therapies are shaping care delivery. Dr Shields is a translational medical oncologist at Indiana University Health in Indianapolis.
In our exclusive interview, Dr Shields highlighted the urgency associated with SCLC treatment, an aggressive malignancy that often presents with rapid symptom onset and widespread metastases. The conversation also underscored the importance of multidisciplinary care. This approach is especially critical in light of expanded treatment options such as che...
Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
In this podcast, experts Narjust Florez, MD, FASCO; David Carbone, MD, PhD; and Edward Garon, MD, MS; discuss the use of KRAS-, NRG1-, MET-, and ROS1-targeting agents to transform patient care in advanced non–small cell lung cancer (NSCLC).
New Trials and Targeted Approaches Advance the Precision of GI Cancer Care: With John Marshall, MD; and Christopher Lieu, MD
In today’s episode, we sat down with John Marshall, MD, and Christopher Lieu, MD, to discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers. Dr Marshall is chief of Hematology and Oncology, a professor of medicine and oncology, and director of the Otto J Ruesch Center for the Cure of Gastrointestinal Cancers at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. Dr Lieu is a professor of medicine, associate director for Clinical Research, and co-director of Gastrointestinal Medical Oncology at the University of Colorado Anschutz and the Un...
T-DXd Trials Transform Treatment for HER2-Positive Breast Cancer: With Sara Nunnery, MD, MSCI; and Kelly E. McCann, MD, PhD
Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.
In today's episode, filmed live onsite at the 43rd Annual Miami Breast Cancer Conference, Dr Nunnery sat down with Kelly E. McCann, MD, PhD, a breast medical oncologist in the University of California system.
Their conversation centered around the evolving HER2-positive breast cancer treatment paradigm. The experts highlighted that although t...
Utilizing Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD
In today’s episode, Jae Park, MD, discussed all things CAR T-cell therapy in acute lymphoblastic leukemia (ALL), touching on topics like where this treatment modality fits into the ALL paradigm, how it affects clinical practice, and how to go about selecting between the multiple FDA-approved options. Dr Park is the chief of the Cellular Therapy Service at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Park began with a conversation about the November 2024 FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) and the October 2021 FDA approval of brexucabtagene autoleucel (brexu-cel; Tec...
Real-World Data Support ctDNA-Guided Treatment Strategies in FGFR2-Altered Cholangiocarcinoma: With Marina Baretti, MD
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, Marina Baretti, MD, discussed the real-world utilization of tissue-free circulating tumor DNA (ctDNA) monitoring in cholangiocarcinoma (CCA). Baretti is an assistant professor and the Jiasheng Chair in Hepato-Biliary Cancer Research at Johns...
ASCO GU 2026 Takeaways
Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to spotlight the most practice-informing data to come out of t...
ctDNA Testing At Progression May Help Detect Resistance and Guide Sequencing in GIST: With Drs Jonathan Trent, MD, PhD, and Neeta Somaiah, MD
In today’s episode of OncLive On Air®, Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, sat down to discuss the evolving role of circulating tumor DNA (ctDNA) testing in gastrointestinal stromal tumors (GIST), as well as the importance of identifying both initial drivers of disease and secondary resistance mechanisms when approaching frontline treatment selection and overall therapeutic sequencing.
Trent is a professor of medicine, associate director of Clinical Research, and director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine, in Florida. Somaiah is a professor and chair of the Dep...
ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD
In today’s episode, we welcomed Wendy Stock, MD, to discuss key recommendations from the ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults, which were published in February. Stock is the Anjuli Seth Nayak Professor of Medicine at University of Chicago Medicine and co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center in Illinois.
In our exclusive interview, Dr Stock explained how specialists, including hematologists, adolescent/young adult (AYA) psychosocial care specialists, pharmacists, methodologists, and patient representatives, contributed to the formation of...
Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD
In today’s episode, we spoke with Colin Vale, MD. Dr Vale is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia.
In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant.
Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role
In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).
Trans-Arterial Micro-Perfusion Could Boost Systemic Chemotherapy Efficacy in Unresectable Pancreatic Cancer: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; and Eric Pletcher, MD
In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC).
Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey. He was joined by:
Anthony Scholer, MD, FACS, FSSO, a surgical oncologist specializing in hepatobiliary surgery at Hackensack Meridian Medical Group and Jersey Shore University Medical Center in Neptune, New Jersey Eric Pletcher, MD, a surgeon specializing in Complex General Sur...Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum
In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.
Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions
Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine.
In...
Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.
Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities
In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.
Leading Breast Oncologists Share Advice and Optimism for Future Women in Oncology: With Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI
In today’s episode, we sat down with Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI, as they shared their stories and perspectives as leading women in oncology in honor of International Women's Day, which is observed annually on March 8. Dr McCann is a breast medical oncologist in the University of California system. Dr Nunnery is a breast medical oncologist with Tennessee Oncology in Nashville.
Forming the backdrop of our exclusive discussion were insights shared during the 2026 OncLive Women in Oncology event, which took place on March 5, 2026, to kick off the 43rd Annual Miami Breast Ca...
FDA Approval Insights: SC Daratumumab Plus VRd Provides Additional Treatment Avenue in Transplant-Ineligible, Newly Diagnosed Myeloma: With Saad Z. Usmani, MD, MBA, FACP, FASCO
In today’s episode, we welcomed Saad Z. Usmani, MD, MBA, FACP, FASCO, to discuss the significance of the January 2026 FDA approval of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).Usmani is chief of Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York, and the recipient of the 2025 Giants of Cancer Care award for multiple myeloma.
In the exclusive interview, Dr Usmani explained the clinical im...
Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.
Incorporating TROP2-Targeted ADCs Into Lung Cancer Treatment Algorithms: With Eric K. Singhi, MD
In today’s episode, we spoke with Eric K. Singhi, MD. Dr Singhi is an assistant professor in the departments of general oncology and thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center in Houston.
Antibody-drug conjugates (ADCs) are rapidly emerging as one of the most exciting therapeutic advances in lung cancer. In this episode, Singhi explored how TROP2-directed ADCs are beginning to reshape treatment strategies across both non–small cell and small cell lung cancer.
Singhi discussed where these agents currently fit within the treatment algorithm for EGFR...
Show Me the Data™: Incorporating the Latest Advances in Immunotherapy and EGFR-Targeted Treatments for Resectable Early-Stage NSCLC
In this podcast, experts Mara Antonoff, MD, FACS; Laura Alder, MD; and Stephanie Worrell, MD, FACS, discuss the latest advances in immunotherapy and EGFR-targeted treatments for patients with resectable, early-stage, non–small cell lung cancer.
Integrating Novel Targets and Translational Insights Into SCLC Practice: With Anne Chiang, MD, PhD
In today’s episode, we spoke with Anne Chiang, MD, PhD, to discuss the rapidly evolving treatment landscape in small cell lung cancer (SCLC) and what this new era of innovation means for patients. Dr Chiang is an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine and associate cancer center director for clinical initiatives at Yale Cancer Center in New Haven, Connecticut.
In our exclusive interview, Chiang reflected on how the field has shifted since the introduction of chemoimmunotherapy in 2018, highlighting improvements in median overall survival and the emergence of lo...
Breast Imaging Advances Emphasize the Importance of Patient-Focused Nuclear Medicine Collaboration: With Megan Kruse, MD; and Sophia O’Brien, MD
In today’s episode, we sat down with Megan Kruse, MD; and Sophia O’Brien, MD. Dr Kruse is a breast medical oncologist at Cleveland Clinic in Ohio. Dr O’Brien is an assistant professor of clinical radiology in the Divisions of Nuclear Medicine and Breast Imaging, as well as the associate program director of the Diagnostic Radiology Residency, at Penn Medicine in Philadelphia, Pennsylvania.
In our exclusive interview, Drs Kruse and O’Brien highlighted the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making, noting the unique role of 18F-fluoroestradiol (FES)–PET/CT in lobular...
Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma
In this podcast, experts Marwan Fakih, MD, Kristen Ciombor, MD, MSCI, and Van Karlyle Morris, MD, discuss the treatment of advanced squamous cell anal carcinoma in the immunotherapy era, with a focus on epidemiology, frontline treatment, and novel approaches to immunotherapy-refractory disease.
Six-Year CheckMate 9LA Data Reinforce Durable Survival in Metastatic NSCLC: With David Carbone, MD, PhD
In today’s episode, we spoke with David Carbone, MD, PhD. Dr Carbone is a professor of internal medicine at The Ohio State University, co-leader of the Translational Therapeutics Program and director of the Thoracic Oncology Center at the Ohio State University Comprehensive Cancer Center–James, as well as the Barbara J. Bonner Chair in Lung Cancer Research in Columbus.
In our exclusive interview, Dr Carbone discussed the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706), which not only reaffirmed the durability of benefit with nivolumab (Opdivo) plus ipilimumab (Yervoy) and chemotherapy but also highlighted particularly stro...
Pumitamig Represents Potential Immunotherapy Strategy for TNBC: With Sarah Sammons, MD
In today’s episode, we sat down with Sarah Sammons, MD. Dr Sammons is associate director of the Metastatic Breast Cancer Program and a senior physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, both in Boston, Massachusetts.
In our exclusive interview, Dr Sammons discussed the rationale for and findings from a phase 2 study (NCT06449222) evaluating the PD-L1– and VEGF-A–directed bispecific antibody pumitamig (BNT327/BMS986545) in patients with locally advanced or metastatic triple-negative breast cancer (TNBC), as well as what these data may mean for the TNBC treatment paradi...
Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD
Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.
Chugh is a clinical profess...
